Mayank Mamtani analyst B. RILEY

Currently out of the existing stock ratings of Mayank Mamtani, 190 are a BUY (89.2%), 23 are a HOLD (10.8%).

Mayank Mamtani

Work Performance Price Targets & Ratings Chart

Analyst Mayank Mamtani works at B. RILEY with a stock forecast success ratio of 28.01% fulfilled within 134.45 days on average. Previously, Mayank Mamtani worked at B. RILEY.

Mayank Mamtani’s has documented 420 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ALT, Altimmune at 13-Feb-2024.

Wall Street Analyst Mayank Mamtani

Analyst best performing recommendations are on NVAX (NOVAVAX).
The best stock recommendation documented was for ALT (ALTIMMUNE) at 11/9/2023. The price target of $8 was fulfilled within 39 days with a profit of $5.55 (226.53%) receiving and performance score of 58.08.

Average potential price target upside

ACST Acasti Pharma ALNA Allena Pharmaceuticals ALT Altimmune ARCT Arcturus Therapeutics Holdings ARWR Arrowhead Pharmaceuticals BIVI Biovie DRNA Dicerna Pharmaceuticals ELOX Eloxx Pharmaceuticals FREQ Frequency Therapeutics GANX Gain Therapeutics ICPT Intercept Pharmaceuticals MDGL Madrigal Pharmaceuticals NGM NGM Biopharmaceuticals NVAX Novavax SAVA Cassava Sciences SEEL Seelos Therapeutics TFFP Tff Pharmaceuticals TGTX TG Therapeutics VXRT Vaxart HTBX Heat Biologics . MBIO Mustang Bio SPPI Spectrum Pharmaceuticals ABUS Arbutus Biopharma Corp CBAY Cymabay Therapeu INMB INmune Bio AGEN Agenus XFOR X4 Pharmaceuticals CGTX Cognition Therapeutics GLMD Galmed Pharmaceuticals Ltd NHWK Nighthawk Biosciences VKTX Viking Therapeutics

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$-0.28 (-10.07%)

1 years 11 days ago

1/1 (100%)

$1.86 (290.63%)




1 years 8 months 4 days ago

1/1 (100%)

$-2.68 (-34.90%)



3 years 5 months 26 days ago

0/1 (0%)

$59.52 (163.16%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Mayank Mamtani is most bullish on?

Potential upside of $15.68 has been obtained for TGTX (TG THERAPEUTICS)

Which stock is Mayank Mamtani is most reserved on?

Potential downside of -$12.54 has been obtained for MDGL (MADRIGAL PHARMACEUTICALS)

What Year was the first public recommendation made by Mayank Mamtani?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?